Kelly McNagny group developed an antibody to target the spread of aggressive tumors
Recently published in Breast Cancer Research, study showed how inhibiting podocalyxin, a protein marker found in many highly aggressive tumours, dramatically slowed the metastasis
Bromme lab discovers collagen degradation mechanisms – potential targets for osteoporosis?
This research not only provides understanding of how cathepsin K breaks down collagen fibers but also opens the door for the design of a new class of drugs selectively targeting the degradation of collagen through cathepsin K.
Deciphering the ‘Glycocode’ of methicillin resistant S. aureus
It is clear that the ‘glycocode’ (complex glycosylation process) plays a vital role in bacterial survival and pathogenicity. The authors believe that TarM and TarS would be ‘lucrative targets for novel therapeutic agents in light of an ever-decreasing antibiotic arsenal’.
The perils of a future without effective antibiotics
WHO report “Antimicrobial resistance: Global report on surveillance” in 2014- the first world-wide report on antimicrobial resistance demonstrates that we may reach the post-antibiotic era this century unless we can take action on many different fronts.
Let’s Come Together: Tuberculosis Virulence Factors
In the current paper, Solomonson and colleagues solved the structure of the ESX-1 secreted virulence factor EspB, demonstrating that it has a pore-like structure, which may facilitate its proposed membranolytic function during pathogenesis.
The Green Side of CBR
On February 12, 2015, Dr. Reinhild Kappelhoff, member of the CBR’s Overall Lab, won the 2015 Green Labs Fund for the project “Lancer Dishwasher 100-hole pipette rack”. It’s not the first time that CBR has won a Green Labs initiative…
“Protease Inhibitors in Drug Discovery” Conference Summary
Protease Inhibitors in Drug Discovery Conference was held on February 26-27, 2015 in San Diego, CA – hosted by GTCbio CBR members, Dr. Dieter Bromme and his postdoctoral fellow, Preety Panwar, attended the Protease Inhibitors in Drug Discovery Conference, where Preety presented her research on “Exosite inhibitors targeting cathepsin K in osteoporosis”. Her travel was […]
How does pathogen inactivation treatment compromise platelet quality? – p38MAPK
Dr. Zhongming Chen, a PDF at Dr. Dana Devine’s laboratory, discovered a novel role of p38MAPK in apoptosis in platelets treated with pathogen inactivation technology.
Karsan Lab Reveals a Novel Promoter of Tumorigenesis
The group demonstrated that loss of RBPJ mimics a Notch activation signal through the derepression of a cohort of genes that are also transcribed following Notch activation.
How flexible are your red blood cells? – Microfluidic deformability
A step forward in transfusion medicine may involve a new application of microfluidics technology to evaluate the quality of stored red blood cells (RBC).